GLP-1 Weight Loss in Manchester, NH: Medicaid Coverage Ended January 1, and Not One Local Clinic Posts a Price
New Hampshire's January 1, 2026 Medicaid cutoff and the defeat of SB 455, five Manchester providers with no published price, and the low-income primary care HPSAs across Central Manchester.
Manchester's adult obesity prevalence is 35.0% (crude rate, BRFSS 2023 via the CDC PLACES 2025 release) 1, 2.2 points above New Hampshire's 32.8% 2. CDC publishes no county-level PLACES estimate, so the state rate is the closest available comparison.
The city has 116,381 residents inside a 426,378-person Manchester-Nashua metro, a median household income of $88,821, and a 4.6% uninsured rate, among the lowest in this series, which makes the state's Medicaid decision, not insurance status, the pivotal access fact here 34.
Manchester carries no active whole-city geographic Primary Care HPSA — a citywide 'Manchester' designation (score 10) is listed 'Proposed For Withdrawal' — but does carry active facility- and population-level shortage designations directly relevant to weight-management access: a Hillsborough geographic-population Primary Care HPSA (score 11, Designated); 'LI-Manchester,' a Low-Income Population Primary Care HPSA (score 10, Designated); the broader 'LI - Central Manchester and Talcotville' Low-Income Population Primary Care HPSA (score 15, Designated, superseding an older score-13 version now proposed for withdrawal); and 'LI - Central Manchester,' a Low-Income Population Dental HPSA (score 18, Designated). Two in-city FQHCs — Amoskeag Health (145 Hollis St) and the City of Manchester Health Dept clinic (1528 Elm St Ste 1) — separately carry their own facility-based Primary Care, Mental Health, and Dental HPSA designations (scores 18-26). No active Mental Health population-group HPSA is currently named for Manchester. Source: HRSA HPSA and HPSA Facilities ArcGIS layers (gisportal.hrsa.gov), queried Aug 28, 2026.56
Specialist access
Manchester has a thin in-city endocrinology/obesity-medicine bench: Dartmouth Health's Dr. Wynn Htun (endocrinology, diabetes & metabolism; also sees patients in Concord), the Manchester VA Medical Center's Dr. Ariana Cannavo, and Dr. Uzma Mohammad Siddiqui, plus Catholic Medical Center's New England Weight Management Institute (769 S Main St) — a MBSAQIP-accredited bariatric surgery and board-certified obesity-medicine program — and Elliot Health System's nutrition/weight-loss services. But per the HPSA data above, the primary-care gateway many patients need before an obesity-medicine referral is itself HRSA-flagged as short-staffed for the city's low-income population (Central Manchester/Talcotville). In practice, most of Manchester's self-pay GLP-1 supply runs not through obesity-medicine specialists but through medspas and hormone-therapy clinics (Alchemy Clinic, Cutting Edge Testosterone Therapy, Pelle Medical Spa, Slim Weight Loss Clinic, Concord MedSpa) — none of which publish specialist credentials or prices for the service on their sites.56
Medicaid coverage note
New Hampshire Medicaid eliminated coverage of GLP-1 medications (Saxenda, Wegovy, Zepbound, and generics) when 'prescribed solely for weight loss,' effective January 1, 2026 — per an NH Division of Medicaid Services notice to all enrolled providers dated October 9, 2025. Coverage remains unchanged only when a GLP-1 is part of a treatment plan for type 2 diabetes, major adverse cardiovascular events (MACE), severe obstructive sleep apnea, or Metabolic Dysfunction-Associated Steatohepatitis (MASH); the notice directs providers to redirect affected members toward Medicaid-covered weight-loss medications (if applicable), physical therapy, and community lifestyle programs instead. A 2026 legislative attempt to restore obesity coverage (Senate Bill 455, sponsored by Sen. Sue Prentiss) was recommended 'Inexpedient to Legislate' by a House committee 13-2 on April 21, 2026, and killed by the full House on May 14, 2026, after DHHS Chief Medical Officer Dr. Jonathan Ballard testified the state 'does not have this money today.' New Hampshire is one of four states (with California, Pennsylvania, South Carolina) that ended Medicaid obesity-GLP-1 coverage on January 1, 2026, leaving 13 state Medicaid programs nationally still covering it for obesity as of 2026.78
New Hampshire Medicaid stopped covering GLP-1s for weight loss on January 1, 2026
New Hampshire Medicaid eliminated coverage of GLP-1 medications, including Saxenda, Wegovy, Zepbound, and generics, when prescribed solely for weight loss, effective January 1, 2026, per an NH Division of Medicaid Services notice to all enrolled providers dated October 9, 2025 7. Coverage remains unchanged only when a GLP-1 is part of a treatment plan for type 2 diabetes, major adverse cardiovascular events, severe obstructive sleep apnea, or metabolic dysfunction-associated steatohepatitis. The notice directs providers to redirect affected members toward Medicaid-covered weight-loss medications where applicable, physical therapy, and community lifestyle programs 7.
A 2026 attempt to restore obesity coverage, Senate Bill 455 sponsored by Sen. Sue Prentiss, was recommended Inexpedient to Legislate by a House committee 13-2 on April 21, 2026, and killed by the full House on May 14, 2026, after DHHS Chief Medical Officer Dr. Jonathan Ballard testified the state does not have this money today 8. New Hampshire is one of four states, with California, Pennsylvania, and South Carolina, that ended Medicaid obesity-GLP-1 coverage on January 1, 2026, leaving 13 state programs nationally still covering it 78.
What GLP-1 care costs in Manchester today
Five Manchester-area providers were checked and none publish a self-pay dollar price for semaglutide or tirzepatide. Alchemy Clinic, 753 Chestnut St, publishes nutrition-consult pricing ($125 initial consult, $75 follow-up, $425 and $375 packages) but states that GLP-1 injectables are prescribed on-label through the respective manufacturer pharmacies, with no dose, frequency, or dollar figure disclosed 9. Cutting Edge Testosterone Therapy LLC, 4 Pershing St, offers a generic GLP-1RA drug class alongside phentermine, without naming semaglutide or tirzepatide, and publishes no prices 10.
Pelle Medical Spa, 159 Frontage Rd, lists GLP-1 peptide therapy with no price shown, notable because the same site does publish prices for some Botox and filler services, making the omission a specific choice rather than a site-wide policy 11. Slim Weight Loss Clinic, 977 Elm St Ste 10b, references medical weight loss injections with no price and a single online-plan conversion path 12. Concord MedSpa's Manchester office, 373 South Willow St Ste D2-1, describes semaglutide at length, mechanism, weekly injection, cardiovascular and kidney benefits, then closes with a consultation request and no number 13. All checked 2026-08-28. That opacity is itself the local finding: Manchester's street price is not publicly verifiable without calling providers directly.
Astra's national price is $68/month for semaglutide and $118/month for tirzepatide on 12-month plans, $816 and $1,416 billed annually. That price is identical in every state Astra serves; there is no city rate.
The primary-care gateway is the designated shortage, not the specialist bench
Manchester carries no active whole-city geographic Primary Care HPSA; a citywide Manchester designation, score 10, is listed Proposed For Withdrawal. Active designations include a Hillsborough geographic-population Primary Care HPSA (score 11, Designated), LI-Manchester, a low-income population Primary Care HPSA (score 10, Designated), the broader LI - Central Manchester and Talcotville low-income population Primary Care HPSA (score 15, Designated, superseding an older score-13 version now proposed for withdrawal), and LI - Central Manchester, a low-income population Dental HPSA (score 18, Designated) 5. Two in-city FQHCs, Amoskeag Health at 145 Hollis St and the City of Manchester Health Dept clinic at 1528 Elm St Ste 1, carry their own facility-based Primary Care, Mental Health, and Dental designations, scores 18 to 26 6. No active mental-health population-group HPSA is currently named for Manchester.
The in-city obesity-medicine bench is thin: Dartmouth Health's Dr. Wynn Htun, who also sees patients in Concord, the Manchester VA Medical Center's Dr. Ariana Cannavo, and Dr. Uzma Mohammad Siddiqui, plus Catholic Medical Center's New England Weight Management Institute at 769 S Main St, an MBSAQIP-accredited bariatric surgery and board-certified obesity-medicine program, and Elliot Health System's nutrition and weight-loss services 56. In practice most of Manchester's self-pay GLP-1 supply runs through medspas and hormone-therapy clinics rather than obesity-medicine specialists, and none of those publish credentials or prices for the service 910111213.
Astra is licensed in all 50 states, New Hampshire included, and its published price does not move with the state's Medicaid decisions. See the New Hampshire GLP-1 overview for statewide context.
Astra treats patients in New Hampshire through state-licensed physicians.
Local options
Alchemy Clinic (753 Chestnut St, Manchester, NH) — Medical Weight Loss Management page publishes nutrition-consult pricing ($125 initial consult, $75 follow-up, $425/$375 packages) but explicitly states GLP-1 injectables are 'prescribed on-label through the respective manufacturer pharmacies' with no dose, frequency, or dollar figure disclosed anywhere on the page. https://alchemyclinic.com/service/medical-weight-loss-management/(checked 2026-08-28)
Cutting Edge Testosterone Therapy LLC (4 Pershing St, Manchester, NH 03102) — Dedicated 'Weight Loss Medication' service page offers a generic GLP-1RA drug class alongside phentermine (semaglutide and tirzepatide are not named specifically anywhere on the page); publishes no dollar prices. CTA is to call the office or book an appointment online. https://www.cuttingedgetestosteronetherapy.com/service/weight-loss-medication(checked 2026-08-28)
Pelle Medical Spa (159 Frontage Rd, Manchester, NH 03103) — Peptide Therapy treatment page lists 'GLP-1 peptide therapy' as an offering with no price shown — notable because the same site does publish prices for some Botox/filler services, making the GLP-1 price omission a specific choice rather than a site-wide no-pricing policy. https://pellemedicalspa.com/treatments/peptide-therapy/(checked 2026-08-28)
Slim Weight Loss Clinic (977 Elm St, Ste 10b, Manchester, NH 03101) — Manchester location page references 'medical weight loss injections' and a personalized treatment plan; no price appears anywhere, and the only conversion path is 'Get a personalized weight loss plan online.' https://slimweightlossclinic.com/locations/manchester-nh/(checked 2026-08-28)
Concord MedSpa - Manchester office (373 South Willow St, Ste D2-1, Manchester, NH 03103) — Weight Management & Body Contouring page describes semaglutide at length (mechanism, weekly injection, cardiovascular/kidney benefits) but states no price anywhere; closes with 'Schedule a consultation with our nursing team.' https://www.concordmedspa.com/services/weight-management-body-contouring(checked 2026-08-28)
Frequently asked questions
What is the obesity rate in Manchester, New Hampshire?
Manchester's adult obesity prevalence is 35.0% (crude rate, BRFSS 2023 data via the CDC PLACES 2025 release), 2.2 percentage points above New Hampshire's statewide rate of 32.8% (BRFSS 2023). CDC does not publish a county-level estimate — PLACES data is place- and state-level only — so the state rate is the closest available comparison.
Does New Hampshire Medicaid cover Ozempic or Wegovy for weight loss in Manchester?
No, not since January 1, 2026. NH Medicaid ended coverage of GLP-1 medications (Saxenda, Wegovy, Zepbound, and generics) prescribed solely for weight loss, per an October 9, 2025 notice from the NH Division of Medicaid Services. Coverage continues only when a GLP-1 is prescribed for type 2 diabetes, major cardiovascular events, severe obstructive sleep apnea, or MASH. A 2026 bill to restore obesity coverage (SB 455) was voted down by the full NH House on May 14, 2026.
How much does semaglutide or tirzepatide cost at a Manchester, NH clinic?
We checked five Manchester-area providers offering GLP-1 or related weight-loss services (Alchemy Clinic, Cutting Edge Testosterone Therapy, Pelle Medical Spa, Slim Weight Loss Clinic, and Concord MedSpa's Manchester office) — none publish a self-pay dollar price for semaglutide or tirzepatide on their own sites. Every one routes visitors to a phone call or consultation to learn pricing. That opacity is itself the local finding: the true street price in Manchester isn't publicly verifiable without calling providers directly.
Is Astra cheaper than local clinics in Manchester?
We can't give a verified yes or no, because no Manchester clinic publishes its GLP-1 price for direct comparison. What we can say is Astra's price is public and fixed nationwide: $68/mo for semaglutide and $118/mo for tirzepatide, billed on a 12-month plan ($816 / $1,416 total) — the same price in Manchester as in every other city Astra serves. Once a specific local clinic discloses its own price, that comparison can be made directly; until then, Astra's number is the only verifiable one in this market.
Is Manchester, NH a designated health professional shortage area (HPSA)?
Not as a single citywide designation — a general 'Manchester' Primary Care HPSA is listed 'Proposed for Withdrawal.' But Manchester does carry several active HRSA shortage designations: a Hillsborough geographic-population Primary Care HPSA, a low-income population Primary Care HPSA covering Manchester, the broader 'Central Manchester and Talcotville' low-income population Primary Care HPSA, and a Central Manchester low-income population Dental HPSA — plus facility-level shortage designations at two in-city FQHCs (Amoskeag Health and the City of Manchester Health Dept clinic).